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Abstract 
Simple, accurate, precise, reproducible, requiring no prior separation and economical procedures for 
simultaneous estimation of Cinnarizine(CNZ) and Dimenhydrinate(DMH)  in tablet dosage form have been 
developed. Method employs formation and solving of simultaneous equation using 250 nm and 277 nm as two 
analytical wavelengths for both drugs in methanol. CNZ and DMH at their respective λmax 250 nm and 277 nm 
shows linearity in a concentration range of 2-12 μg /ml and 10-35 μg /ml. Recovery studies for CNZ 98.9-
100.75% and 96.16-100.69% for DMH in case of simultaneous equation method confirming the accuracy of 
the proposed method. The proposed method is recommended for routine analysis since it is rapid, simple, 
accurate and also sensitive and specific. 
Keywords: Cinnarizine, Dimenhydrinate, Validation 
 
1. Introduction 
(Cinnarizine (CNZ) is a white powder. 
Chemically it is (E)-1-(Diphenylmethyl)-4-(3-
phenylprop-2-enyl) piperazine1,2 (Fig. 1: A). It is 
antihistaminic agent and calcium channel blocker. It 
has calcium-channel blocking activity selective for 
arterial smooth muscles. It also has some 
antihistamine activity. Cinnarizine acts as a sedative. 
It also improves microcirculation by reducing 
ischemia-induced blood viscosity. Dimenhydrinate 
(DMH) is white crystalline odourless powder. 
Chemically, it is 8-chloro-1,3-dimethyl-2,6-dioxo-
2,3,6,7-tetrahydro-1H-purin-7-ide; [2-
(diphenylmethoxy)ethyl]dimethylazanium1,2 (Fig. 1: 
B). It is very soluble in alcohol and practically 
insoluble in ether3. It is antiemetic agent and 
antihistaminic agents. The mechanism by which some 
antihistamines exert their antiemetic, anti–motion 
sickness, and antivertigo effects is not precisely 
known but may be related to their central 
anticholinergic actions. They diminish vestibular 
stimulation and depress labyrinthine function. An 
action on the medullary chemoreceptive trigger zone 
may also be involved in the antiemetic effect. 
Dimenhydrinate is a competitive antagonist at the 
histamine H1 receptor, which is widely distributed in 
the human brain. Dimenhydrinate's anti-emetic effect 
is probably due to H1 antagonism in the vestibular 
system in the brain1.  
The combination of Cinnarizine and 
Dimenhydrinate is indicated as antivertigo agents4.  
DMH and CNZ are official in British Pharmacopeia 
and Indian Pharmacopeia respectively. Many methods 
have been reported in literature for determination of 
CNZ individually and with other drugs in 
combination.5-8 and for dimenhydrinate individually 
and with other drugs9-11 However there is no UV 
spectrophotometric method  reported for the 
simultaneous equation method of CNZ and DMH in 
pharmaceutical preparations in literature survey. The 
objective of the present work is to develop and 
validate new analytical methods for simultaneous 
determination of CNZ and DMH in tablet dosage 
form. 
Figure 1: (A) Structure of Cinnarizine (B) 
Structure of Dimenhydrinate 
           
       (A)                               (B) 
2. Experimental 
2.1 Materials and Methods 
A double-beam Shimadzu UV-Visible 
spectrophotometer 1700 (Pharma spec) was used with 
wavelength accuracy of ± 0.5 nm and a pair of 1-cm 
matched quartz cells, was used to measure absorbance 
of the resulting solution. All weighing were done on 
electronic balance (Model Shimadzu BL-220H). All 
statistical calculations were carried out using 
Microsoft Excel 2007 analytical tool.  
Analytically pure CNZ and DMH were 
procured as gift sample from Kamud Pharmaceuticals 
Ltd. and Ajanta Pharmaceutical Pvt. Ltd., (Bombay, 
India). Methanol (E. Merck, Mumbai, India) 
analytical grade was used as diluents. Tablet 
formulation (VERTIZAC, Ajanta Pharmaceutical Pvt. 
Ltd) containing labelled amount of 20 mg of 
Cinnarizine and 40 mg of Dimenhydrinate were 
purchased from local market. 
2.2 Preparation of solutions 
Accurately weighed 10mg of CNZ and 
DMH standards were transferred to separate 10ml 
volumetric flask and dissolved in 10 ml Methanol. 
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The flasks were shaken and volume was made up to 
the mark with Methanol to give solutions containing 
1000 µg/ml CNZ and 1000 µg/ml DMH  respectively. 
2.3 Methodology 
Selection of analytical wavelengths was 
done by taking pure samples of CNZ and DMH which 
were separately dissolved in methanol to give two 
solutions of 10 μg/ml, respectively. They were 
scanned in the wavelength range of 200–400 nm. 
From the overlain spectra (Figure 2), wavelengths 
250 and 277nm were selected for the formation of 
simultaneous equations. For constructing a calibration 
curves, two series of different concentrations in range 
of 2-12 μg/mL for CNZ and 10-35 μg/mL for DMH 
were prepared from stock solutions. The calibration 
curves were plotted at 250 and 277 nm. The 
absorptivities (A1%, 1 cm) of both the drugs at both 
the wavelengths were determined. These calculated 
values were the mean of five independent 
determinations. Concentrations in the sample were 
obtained by using following equations- 
 
          A1 ay2 – A2 ay1 
Cx = -----------------------. . . . . . Eq. (i) 
          ax1ay2 ─ ax2ay1 
  
 
         A1 ax2 – A2 ax1 
Cy = ----------------------- ……Eq. (ii) 
         ay1ax2 ─ ay2ax1 
 
Where, A1 and A2 are absorbance of mixture at 
250nm and 277 nm respectively,  
             ax1 and ax2 are absorptivities of CNZ at λ1 
and λ2 respectively 
             ay1 and ay2 are absorptivities of DMH at λ1 
and λ2 respectively.  
             Cx and Cy are concentrations of CNZ and 
DMH respectively. 
 
2.4 Method Validation 
The proposed method was validated 
according to International Conference on 
Harmonization (ICH) guidelines12. 
2.4.1 Linearity and range 
Developed analytical method shows linearity 
response over the range of 2-12 μg/ml for CNZ and 
10-35 μg/ml for DMH at 250nm and 277nm 
respectively. 
2.4.2 Precision 
The intra-day and inter-day precision study 
of the proposed simultaneous equation 
spectrophotometric method was carried by estimating 
responses three times on the same day and on three 
different days (first, second, third day) for three 
different concentrations of CNZ (2, 6, 10 µg/ ml) and 
DMH (20, 25, 30 µg/ ml) and the results reported in 
terms of percentage relative standard deviation 
(%RSD). 
2.4.3 Accuracy 
The accuracy of the method was determined 
by calculating recoveries of CNZ and DMH by 
method of standard additions. Known amount of CNZ 
(50%, 100% and 150%) and DMH (50%, 100% and 
150%) were added to a pre quantified sample 
solutions and the amount of CNZ and DMH were 
estimated by measuring response at the appropriate 
wavelengths. The recovery was verified by estimation 
of drugs in triplicate preparations at each specified 
concentration levels. 
2.4.4 LOD and LOQ 
Calibration curve was repeated for 5 times 
and the standard deviation (SD) of the intercepts was 
calculated. Then LOD and LOQ were measured as 
follows 
LOD = 3.3 × σ/S 
LOQ = 10 × σ/S  
Where, σ = the standard deviation of the y - 
intercept 
              S = slope of the calibration curve. 
2.5 Solution stability 
Solution stability of the method was studied 
by observing the stability of both the drug solutions at 
25 ± 2°C for 24 h. 
2.6 Analysis of marketed formulation 
The pharmaceutical dosage form used in this 
study was VERTIZAC tablets with a content of 20mg 
CNZ and 40mg DMH as per tablet. Twenty tablets of 
brand VERTIZAC tablets were weighed and finely 
powdered. Accurately weighed tablet powder 
equivalent to 20 mg of cinnarizine and 40mg of 
Dimenhydrinate taken in 10ml volumetric flask. Few 
ml of methanol was added and sonicated for 5 min. 
The volume was made upto the mark with methanol. 
Aliquot portion of this solution was further diluted to 
achieve final concentration of 10μg/ml for CNZ and 
20µg/ml DMH. The absorbances were noted at 
respective wavelengths. The concentration of each 
drug in tablet formulation was determined using 
above methods. 
 
3. Result and Discussion 
A simultaneous equation spectrophotometric 
method was successfully developed for determination 
of CNZ and DMH from their combined dosage form. 
The proposed simultaneous equation method 
shows good linearity in the concentration range of 2-
12 µg/ml of CNZ and 10-35 µg/ml of DMH with 
correlation co-efficient 0.995 for CNZ and 0.998 for 
DMH, respectively. (Table 2)  
The % RSD values for CNZ and DMH were 
found to be 0.54 % and 0.38 %, respectively. The low 
values of relative standard deviation (less than 2 %) 
indicate that the proposed method is repeatable. The 
% RSD values for intraday study was found to be 
0.52 - 0.65 % and 0.11 - 0.39 % for CNZ and DMH, 
respectively. The % RSD values for interday study 
was found to be 0.63 - 0.73 % and 0.10 - 0.58 % for 
CNZ and DMH, respectively. The low RSD value 
indicates that the proposed method is precise (Table 3 
- 4). The detection limit of CNZ and DMH were 0.06 
and 0.55 μg/ml, while quantitation limit of CNZ and 
DMH were 0.206 and 1.680 μg/ml, respectively. The 
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above data shows that a nanogram quantity of both 
the drugs can be accurately and precisely determined. 
The validation parameters are summarized in Table 1. 
The accuracy of the method was determined 
by calculating recoveries of CNZ and DMH by 
method of standard additions. The % recoveries were 
found to be 98.9 % – 100.75% for CNZ and 96.16 % - 
100.69 % for DMH (Table 5). The results of recovery 
studies indicate that the proposed method is accurate. 
The proposed validated method was 
successfully applied to determine CNZ and DMH in 
tablet dosage form. The results obtained for CNZ and 
DMH were comparable with the corresponding 
labelled amounts (Table 6). No interference of the 
excipients with the absorbance of interest appeared; 
hence the proposed method is applicable for the 
routine simultaneous estimation of CNZ and DMH in 
pharmaceutical dosage forms. 
Table 1: Summary of validation parameters 
Parameters CNZ DMH 
Limit of Detection 0.06 0.55 
Limit of Quantitation 0.206 1.680 
Accuracy (%) 98.9-100.75 96.16-100.69 
Precision 
Intraday (n = 3) 0.52 - 0.65 % 0.11 - 0.39 % 
Interday (n = 3) 0.63 - 0.73 % 0.10 -0.58 % 
Repeatability (RSD, n = 6) 0.531 % 0.424 % 
Solvent suitability Suitable for 24 hrs. Suitable for 24 hrs. 
Table 2: Statistical data of CNZ and DMH 
Parameters CNZ at 250nm DMH at 277nm 
Linear range 2 – 12 µg/ml 10-15 µg/ml 
Slope 0.022 0.019 
Intercept 0.046 0.037 
Standard deviation of intercept 0.00044 0.00324 
Standard deviation of slope 0.0009 0.0004 
Regression Coefficient (r2) 0.995 0.998 
Table 3: Determination of Precision for CNZ 
CNZ 
Conc. 
(μg/ml) 
Intraday 
Mean ± SD (n =3) 
% RSD 
Interday 
Mean ± SD (n =3) 
% RSD 
At250nm 
2 0.088±0.000577 0.653 0.088±0.00557 0.651 
6 0.190±0.001 0.523 0.182±0.00114 0.636 
10 0.284±0.00173 0.610 0.310±0.00577 0.737 
At277nm 
2 0.03067±0.00058 1.882 0.03067 ± 0.00058 1.882 
6 0.03633±0.00058 1.589 0.03667±0.00058 1.574 
10 0.04367±0.00058 1.322 0.04767±0.00058 1.211 
Table 4: Determination of precision for DMH 
DMH 
Conc. 
(μg/ml) 
Intraday 
Mean ± SD (n =3) 
% RSD 
Interday 
Mean ± SD (n =3) 
% RSD 
At250nm 
20 0.2832±0.00283 1.01 0.306±0.00371    1.34 
25     0.339±0.00084 0.23 0.4075±0.0018 0.372 
30     0.453±0.00261 0.386      0.486±0.0074 0.51 
At277nm 
20     0.442±0.001732 0.391      0.45±0.00264 0.587 
25     0.5233±0.000577 0.110   0.5286±0.00057 0.109 
30     0.6336±0.00208 0.328   0.6397±0.00173 0.271 
Table 5: Determination of accuracy 
% 
Level 
Amount of drug 
added (μg/ml) 
Recovered amount 
of drug (μg/ml) 
% Recovery 
CNZ 
(μg/ml) 
DMH 
(μg/ml) 
CNZ 
(μg/ml) 
DMH 
(μg/ml) 
CNZ DMH 
50 6 15 5.914 15.06 98.74±0.28 100.38±0.17 
100 8 20 8.070 20.06 100.75±0.088 100.69±0.22 
150 10 25 9.89 24.04 98.9±0.26 96.16±0.30 
Table 6: Assay Results of Marketed Formulation 
Formulation 
Actual concentration 
(μg/ml) 
Amount obtained (μg/ml) %  
CNZ 
%  
DMH 
CNZ DMH CNZ  DMH  
Tablet 20.0 40.0 19.75  39.78  98.75%  99.45%  
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Figure 2: Overlain spectrum of CNZ and DMH in Methanol of 10ppm 
 
4. Conclusions  
Sensitive, precise and accurate simultaneous 
UV spectroscopic method was developed and 
validated. The proposed method is accurate, precise, 
reproducible, and economical and can be successfully 
used for routine analysis of simultaneous estimation 
of CNZ and DMH. The method was validated as per 
ICH guidelines in terms of linearity, accuracy, 
precision, limits of detection (LOD) and 
quantification (LOQ), and robustness. The proposed 
method can be used for quality control assay of CNZ 
and DMH in their pharmaceutical dosage form. 
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